Although this study analyzed the cost-effectiveness of pemigatinib treatment in advanced ICC patients with FGFR2 fusions/rearrangements, we adopted a similar approach as our previous work and applied most of the parameters. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.